Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $13.74, for a total transaction of $109,920.00. Following the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at $109,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of CORT opened at $13.01 on Friday. The firm has a market cap of $1.55 billion, a PE ratio of 29.57 and a beta of 1.80. Corcept Therapeutics Incorporated has a 12-month low of $11.21 and a 12-month high of $25.96.
Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.02). The company had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $67.42 million. Corcept Therapeutics had a net margin of 63.79% and a return on equity of 32.96%. The firm’s revenue for the quarter was up 50.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 earnings per share. As a group, sell-side analysts predict that Corcept Therapeutics Incorporated will post 0.6 EPS for the current fiscal year.
Several research firms have commented on CORT. BidaskClub raised shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald set a $17.00 target price on shares of Corcept Therapeutics and gave the company a “hold” rating in a research note on Monday, October 1st. ValuEngine lowered shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 5th. B. Riley lowered their target price on shares of Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, August 13th. Finally, Zacks Investment Research raised shares of Corcept Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Corcept Therapeutics has a consensus rating of “Hold” and an average price target of $21.83.
WARNING: “Robert S. Fishman Sells 8,000 Shares of Corcept Therapeutics Incorporated (CORT) Stock” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/11/robert-s-fishman-sells-8000-shares-of-corcept-therapeutics-incorporated-cort-stock.html.
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Recommended Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.